Failed on Paper, Not Necessarily in Fact
A 58-year-old whose erectile dysfunction hasn't responded to sildenafil — and a debate over whether he has genuinely failed the drug, or never actually been given a fair trial of it.
Dominic A. runs a small landscaping company and has been managing what he describes as sildenafil failure for the past seven months, since his primary care physician started him on 50mg as needed after his erectile difficulties became a source of real strain in his marriage of twenty-two years. He was referred to urology specifically because his primary care physician, before adding anything else, wanted a specialist to confirm whether he had genuinely failed the drug or simply never had an adequate trial of it — a distinction that turned out to matter directly once the actual history was taken.
On direct questioning, Dominic had been taking sildenafil inconsistently at 50mg, frequently within an hour of a large dinner, and had attempted intercourse successfully fewer than four times across the full seven months rather than the eight-to-ten-attempt trial most guidelines consider adequate before calling a dose a true failure. High-fat meals meaningfully delay and blunt sildenafil's peak absorption, which is what makes his own mistimed attempts so hard to read as true non-response.
His labs, drawn as part of the same referral workup, showed a testosterone of 261 ng/dL, confirmed on a second morning draw — genuinely low, not borderline the way Marcus T.'s case elsewhere in this volume is. That finding changes what's actually being asked here: it's not simply whether Dominic needs a better-run trial of sildenafil, but whether his confirmed hypogonadism is itself contributing to his erectile dysfunction and, more specifically, to any real pharmacologic non-response once the trial is properly conducted. Testosterone independently supports both central sexual desire and peripheral nitric oxide signaling in the erectile pathway that PDE5 inhibitors act on downstream, which is the mechanistic basis for combination therapy in hypogonadal men specifically, not a general-purpose fix for erectile dysfunction at normal hormone levels.
There's a second layer worth naming honestly, since Dominic asked about it directly once the labs came back: the trials showing that testosterone add-back converts PDE5-inhibitor non-responders into responders enrolled hypogonadal men who had genuinely failed an adequate trial — eight to ten properly-timed attempts at a titrated dose. On fewer than four attempts, most of them taken within an hour of a heavy meal, Dominic does not yet match that entry description, which is the awkward part of reading those results onto him today rather than after the trial has been run correctly. Neither intervention on its own answers both open questions in his case; run together, a corrected sildenafil trial and testosterone replacement let his eventual response actually reflect what each drug can do for him, rather than leaving one confounded by the other.
Urology referral, checking the failure before treating it
Before we call this a real sildenafil failure, I want to name what the history actually shows: fewer than four genuine attempts across seven months, frequently within an hour of a heavy meal, which meaningfully delays and blunts absorption. That's not the eight-to-ten adequately-timed attempts most guidelines want before a dose gets labeled a true non-response. A real share of stated PDE5 failures turn out to be technique failures once you actually ask.
I agree the technique history matters and should be fixed regardless of what else we do. But I don't think it fully explains this, because his testosterone came back confirmed at 261, genuinely low, not the borderline read Marcus T.'s case elsewhere in this volume shows. Real trial data on hypogonadal men who fail PDE5 inhibitor monotherapy shows testosterone add-back converts a meaningful share of them into responders — that's a distinct mechanism from simply retrying the same drug more carefully, since testosterone supports both central desire and the peripheral nitric oxide signaling PDE5 inhibitors act downstream of.
You're right that a bad trial can look exactly like a true failure from the outside — but a confirmed hormonal deficiency sitting underneath a bad trial is still worth treating on its own, whatever the sildenafil trial ends up showing once it's actually run correctly.
Then there's no reason to sequence these — do both together. Restart sildenafil at a properly titrated dose, taken on an empty stomach with adequate time before attempted intercourse, alongside testosterone replacement for his confirmed deficiency, and reassess in eight weeks with an honest count of adequately-timed attempts. That answers both questions at once instead of making him wait through a technique-only trial before we address a real hormonal finding sitting in his own labs.
Agreed: sildenafil restarted at a corrected dose and timing alongside testosterone replacement for his confirmed deficiency, with reassessment at eight weeks tracking adequately-timed attempts specifically, not just a yes-or-no on overall improvement.
The urologist's point that many stated PDE5 failures are technique failures was not overridden by treating his testosterone — both were pursued together precisely because neither voice could rule out the other's explanation from his history alone, and Dominic didn't need the group to resolve that question before starting real treatment.